Aller au contenu principal
2025 conference-abstract

Abstract P4-11-25: Enhancing Care of HR+/HER2- Early Breast Cancer Patient At Risk of Recurrence Through an Expansive Curriculum

0Citations signalées, ce qui n’est pas une note de qualité
0Institutions déclarées
0Pays d’affiliation déclarés

Le résumé fourni par la source

Abstract Introduction: Although therapies for patients with HR+/HER2- early breast cancer (EBC) have been available for several years, a number of clinical gaps remain, minimizing the optimization of care in this patient population. In an effort to overcome these gaps, a large educational curriculum was developed to improve the learner’s ability to determine which patients are at high-risk for recurrence and how to implement and maintain the patient on appropriate therapy. Methods: The curriculum included 11 online CME activities that were distributed between October 2023 and May 2024. The goal of this curriculum was to enhance oncologist’s knowledge, competence, and confidence along three core learning areas: identification of patients with HR+/HER2- EBC at high risk for recurrence, selection of optimal treatment for high-risk patients, and improvement of patient’s adherence to therapy. Educational impact was assessed with repeated pairs design. Oncologists were asked pre-education and post-education knowledge/competence and confidence questions. These questions were based on the identified education gaps and designed to assess if the learning objectives were met. Data were collected from October 2023 to May 2024. Statistical significance was assessed using McNemar’s test (P < .05 level). Results: A total of 20456 global oncologists participated in these activities, of which 3564 completed the activities. The assessment questions and the outcomes data were divided into three core learning areas, three levels of learning, and by geographical area to determine impact of education. IDENTIFICATION OF RISKGeographical Area/Learning Level (n) Pre% Post% Abs Change% P ValueKNOWLEDGEUS (117) 44 47 3 <.05OUS (217) 52 61 9 <.001COMPETENCEUS (271) 65 75 10 <.001OUS (374) 67 75 8 <.001CONFIDENCEUS (376) 19 24 5 <.001OUS (84) 28 36 8 <.001 TREATMENT SELECTIONGeographical Area/Learning Level (n) Pre% Post% Abs Change% P ValueKNOWLEDGEUS (190) 67 70 3 --OUS (231) 76 80 4 <.01COMPETENCEUS (381) 46 61 15 <.001OUS (497) 50 61 11 <.05CONFIDENCEUS (410) 12 20 8 <.001OUS (84) 22 33 17 <.001 ADHERENCE TO THREAPYGeographical Area/Learning Level (n) Pre% Post% Abs Change% P ValueKNOWLEDGEUS (56) 67 69 2 --OUS (105) 73 77 4 <.05COMPETENCEUS (165) 58 64 8 <.05OUS(245) 56 64 9 <.05CONFIDENCEUS (130) 17 21 4 <.001OUS (80) 21 39 18 <.05 Conclusions: The results of these activities have led to a significant increase in the knowledge, competence and confidence of oncologists through all segmentations of the core learning areas, learning levels, and geographical areas assessed. Despite this positive growth many gaps still remain, and further education is needed to minimize those gaps. Citation Format: Urvi Patel, Nabil Dorkhom, Victoria Phoenix, Jordan Schwartz, Katie Lucero. Enhancing Care of HR+/HER2- Early Breast Cancer Patient At Risk of Recurrence Through an Expansive Curriculum [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P4-11-25.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Abstract P4-11-25: Enhancing Care of HR+/HER2- Early Breast Cancer Patient At Risk of Recurrence Through an Expansive Curriculum
Date Crossref
13/06/2025
Éditeur
American Association for Cancer Research (AACR)
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les sujets associés

Breast Cancer Treatment StudiesCancer Treatment and Pharmacology

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.